Aspen Aerogels (NYSE:ASPN) Trading Down 11% – Should You Sell?

Aspen Aerogels, Inc. (NYSE:ASPN)’s stock price was down 11% during trading on Friday . The company traded as low as $5.67 and last traded at $6.1350. Approximately 672,679 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 1,592,493 shares. The stock had previously closed at $6.89.

Key Stories Impacting Aspen Aerogels

Here are the key news stories impacting Aspen Aerogels this week:

• Positive Sentiment: Aspen reported second-quarter revenue of $49.85 million, exceeding the $42.42 million consensus estimate. Its adjusted loss of $0.22 per share was also slightly better than the expected $0.23 loss. Aspen Aerogels Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Thermal Barrier revenue reached $29.5 million, an 81% sequential increase, highlighting momentum in Aspen’s electrification-related business. The company also raised its 2026 European Thermal Barrier revenue outlook to $20 million-$30 million. Aspen Aerogels Second-Quarter Results
• Positive Sentiment: Third-quarter revenue guidance of $65 million-$80 million is well above the $56.6 million analyst consensus, while adjusted EBITDA guidance of $7 million-$15 million suggests improving operating leverage. EPS guidance of a $0.07-$0.11 loss is also better than the expected $0.13 loss. Aspen Aerogels Guidance
• Positive Sentiment: Jaguar Land Rover selected Aspen’s PyroThin technology for two next-generation vehicle architectures, adding evidence of potential future automotive demand. Q2 2026 Earnings Presentation
• Neutral Sentiment: Aspen Aerogels’ inclusion in Russell 1000 coverage may improve visibility and potentially attract index-related investor interest, although the direct financial impact is uncertain. Aspen Aerogels Russell 1000 News
• Negative Sentiment: The company remains unprofitable: its second-quarter loss widened from $0.04 per share a year earlier to $0.22, with negative net margin and return on equity. This continuing cash-burn and execution risk may be limiting the market’s reaction to the otherwise favorable results. Aspen Aerogels Q2 Earnings Snapshot

Analyst Upgrades and Downgrades

Several research firms have weighed in on ASPN. Barclays lifted their price objective on Aspen Aerogels from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Monday, May 11th. Wall Street Zen upgraded Aspen Aerogels from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Roth Capital reissued a “buy” rating and issued a $7.75 target price on shares of Aspen Aerogels in a report on Friday. B. Riley Financial restated a “buy” rating on shares of Aspen Aerogels in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.69.

Aspen Aerogels Trading Down 9.1%

The stock has a market cap of $519.24 million, a P/E ratio of -4.09 and a beta of 2.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.54 and a current ratio of 2.89. The stock’s fifty day moving average is $5.51 and its 200 day moving average is $4.42.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Thursday, August 6th. The construction company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $49.85 million for the quarter, compared to analysts’ expectations of $42.42 million. Aspen Aerogels had a negative return on equity of 29.30% and a negative net margin of 62.45%.Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. As a group, equities research analysts predict that Aspen Aerogels, Inc. will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of Aspen Aerogels

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Aspen Aerogels in the second quarter worth $33,457,000. Oaktop Capital Management II L.P. bought a new position in Aspen Aerogels during the second quarter valued at $32,769,000. Vanguard Group Inc. raised its stake in shares of Aspen Aerogels by 0.5% in the third quarter. Vanguard Group Inc. now owns 4,510,370 shares of the construction company’s stock valued at $31,392,000 after acquiring an additional 22,686 shares during the period. Needham Investment Management LLC raised its stake in shares of Aspen Aerogels by 26.5% in the fourth quarter. Needham Investment Management LLC now owns 4,351,700 shares of the construction company’s stock valued at $12,315,000 after acquiring an additional 912,000 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Aspen Aerogels by 237.9% in the 4th quarter. Invesco Ltd. now owns 4,129,934 shares of the construction company’s stock worth $11,688,000 after acquiring an additional 2,907,558 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.